Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: A consensus statement

• Autores: Boguszewski, Margaret C.S.; Boguszewski, Cesar L.; Chemaililly, Wassim; Cohen, Laurie E.; Gebauer, Judith; Higham, Claire; Hoffman, Andrew R.; Polak, Michel; Yuen, Kevin C.J.; Alos, Nathalie; Antal, Zoltan; Bidlingmaier, Martin; Biller, Beverley M.K.; Brabant, George; Choong, Catherine S.Y.; Cianfarani, Stefano; Clayton, Peter E.; Coutant, Regis; Cardoso Demartini, Adriane A.; Fernandez, Alberto; Grimberg, Adda; Guðmundsson, Kolbeinn; Guevara Aguirre, Jaime; K Y Ho, Ken; Horikawa, Reiko; Isidori, Andrea M.; Otto Lunde Jørgensen, Jens; Kamenicky, Peter; Karavitaki, Niki; Pennisi, Patricia Alejandra
• Año de publicación: 2022
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: Intracranial tumour survivors; GH; Safety
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

Growth hormone (GH) has been used for over 35 years, and its safety and efficacy has been studied extensively. Experimental studies showing the permissive role of GH/insulin-like growth factor 1 (IGF-I) in carcinogenesis have raised concerns regarding the safety of GH replacement in children and adults who have received treatment for cancer and those with intracranial and pituitary tumours. A consensus statement was produced to guide decision-making on GH replacement in children and adult survivors of cancer, in those treated for intracranial and pituitary tumours and in patients with increased cancer risk. With the support of the European Society of Endocrinology, the Growth Hormone Research Society convened a Workshop, where 55 international key opinion leaders representing 10 professional societies were invited to participate. This consensus statement utilized: (1) a critical review paper produced before the Workshop, (2) five plenary talks, (3) evidence-based comments from four breakout groups, and (4) discussions during report-back sessions. Current evidence reviewed from the proceedings from the Workshop does not support an association between GH replacement and primary tumour or cancer recurrence. The effect of GH replacement on secondary neoplasia risk is minor compared to host- and tumour treatment-related factors. There is no evidence for an association between GH replacement and increased mortality from cancer amongst GH-deficient childhood cancer survivors. Patients with pituitary tumour or craniopharyngioma remnants receiving GH replacement do not need to be treated or monitored differently than those not receiving GH. GH replacement might be considered in GH-deficient adult cancer survivors in remission after careful individual risk/benefit analysis. In children with cancer predisposition syndromes, GH treatment is generally contraindicated but may be considered cautiously in select patients.
Fil: Boguszewski, Margaret C.S.. Universidade Federal do Paraná; Brasil
Fil: Boguszewski, Cesar L.. Universidade Federal do Paraná; Brasil
Fil: Chemaililly, Wassim. University of Pittsburgh; Estados Unidos
Fil: Cohen, Laurie E.. Albert Einstein College of Medicine; Estados Unidos
Fil: Gebauer, Judith. University Hospital Schleswig-holstein-campus Lübeck; Alemania
Fil: Higham, Claire. University of Manchester; Reino Unido
Fil: Hoffman, Andrew R.. University of Stanford; Estados Unidos
Fil: Polak, Michel. Hôpital Universitaire Necker Enfants Malades; Francia
Fil: Yuen, Kevin C.J.. University of Arizona; Estados Unidos
Fil: Alos, Nathalie. University of Montreal; Canadá
Fil: Antal, Zoltan. Weill Cornel Medicine New York Presbyterian Hospital; Estados Unidos. Memorial Sloan-kettering Cancer Center; Estados Unidos
Fil: Bidlingmaier, Martin. Medizinische Klinik und Poliklinik IV; Alemania
Fil: Biller, Beverley M.K.. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;
Fil: Brabant, George. University of Manchester; Reino Unido
Fil: Choong, Catherine S.Y.. University of Western Australia; Australia
Fil: Cianfarani, Stefano. Irccs "bambino Gesu" Children´s Hospital; Italia. Università di Roma; Italia
Fil: Clayton, Peter E.. University of Manchester; Reino Unido
Fil: Coutant, Regis. Universidad San Francisco de Quito; Ecuador
Fil: Cardoso Demartini, Adriane A.. Universidade Federal do Paraná; Brasil
Fil: Fernandez, Alberto. Universidad de Mostoles; España
Fil: Grimberg, Adda. University of Pennsylvania; Estados Unidos
Fil: Guðmundsson, Kolbeinn. The National University Hospital of Iceland; Islandia
Fil: Guevara Aguirre, Jaime. Universidad San Francisco de Quito; Ecuador
Fil: K Y Ho, Ken. The Garvan Institute of Medical Research and St. Vincent Hospital; Australia
Fil: Horikawa, Reiko. National Center for Child Health and Development; Japón
Fil: Isidori, Andrea M.. Università degli Studi di Roma "La Sapienza"; Italia
Fil: Otto Lunde Jørgensen, Jens. University Aarhus; Dinamarca
Fil: Kamenicky, Peter. Centre de Référence des Maladies Rares de l'Hypophyse; Francia
Fil: Karavitaki, Niki. The University Of Birmingham (tub);
Fil: Pennisi, Patricia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas "Dr. César Bergada". Gobierno de la Ciudad de Buenos Aires. Centro de Investigaciones Endocrinológicas "Dr. César Bergada". Fundación de Endocrinología Infantil. Centro de Investigaciones Endocrinológicas "Dr. César Bergada"; Argentina